Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment.

Journal Article (Journal Article;Multicenter Study)

OBJECTIVE: To report a multi-center experience with the novel Hemodialysis Reliable Outflow (HeRO) vascular access graft. MATERIALS AND METHODS: Four centers conducted a retrospective review of end stage renal disease patients who received the HeRO device from implant to last available follow-up. Data is available on 164 patients with an accumulated 2092.1 HeRO implant months. RESULTS: At 6 months, HeRO primary and secondary patency is 60% and 90.8%, respectively and at 12 months, 48.8% and 90.8%, respectively. At 24 months, HeRO had a primary patency of 42.9% and secondary patency was 86.7%. Interventions to maintain or re-establish patency have been required in 71.3% of patients (117/164) resulting in an intervention rate of 1.5/year. Access related infections have been reported in 4.3% patients resulting in a rate of 0.14/1000 implant days. CONCLUSIONS: In our experience the HeRO device has performed comparably to standard AVGs and has proven superior to TDCs in terms of patency, intervention, and infection rates when compared to the peer-reviewed literature. As an alternative to catheter dependence as a means for hemodialysis access, this graft could reduce the morbidity and mortality associated with TDCs and have a profound impact on the costs associated with catheter related infections and interventions.

Full Text

Duke Authors

Cited Authors

  • Gage, SM; Katzman, HE; Ross, JR; Hohmann, SE; Sharpe, CA; Butterly, DW; Lawson, JH

Published Date

  • July 2012

Published In

Volume / Issue

  • 44 / 1

Start / End Page

  • 93 - 99

PubMed ID

  • 22580402

Electronic International Standard Serial Number (EISSN)

  • 1532-2165

Digital Object Identifier (DOI)

  • 10.1016/j.ejvs.2012.04.011


  • eng

Conference Location

  • England